Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration?
Author(s): Aweeka FT, Brody SR, Jacobson M, Botwin K, Martin-Munley S Affiliation(s): Department of Clinical Pharmacy, University of California, San Francisco, USA. Publication date & source: 1998-03, Clin Ther., 20(2):232-43. Publication type: Clinical Trial; Randomized Controlled Trial Foscarnet, an antiviral agent used in the treatment of cytomegalovirus infection, and zalcitabine, an antiretroviral nucleoside analogue used in the treatment of human immunodeficiency virus infection, are commonly used concomitantly. Foscarnet and zalcitabine may interact pharmacokinetically, as both compounds are partially eliminated by renal tubular secretion. Owing to dose-related toxicities associated with these two drugs, it is essential that we have data regarding their pharmacokinetic disposition during concomitant therapy. Twelve patients randomly received either foscarnet (four doses) or zalcitabine (five doses) (Phase 1), followed by concomitant foscarnet (four doses) and zalcitabine (six do
